Interaction Checker

Interaksi Ikosapen etil

Ikosapen etil (Vascepa), golongan asam lemak omega-3, memiliki 33 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 0 mayor, 33 moderat, 0 minor, dan 0 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Interaksi dari label

Interaksi moderat (33)

  • Amlodipin dan atorvastatinpenghambat kanal kalsium dihidropiridinModerat

    In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (label Ikosapen etil, Peringatan dan perhatian)

  • ApiksabanantikoagulanModerat

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (label Ikosapen etil, Interaksi obat)

  • ArgatrobanantikoagulanModerat

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (label Ikosapen etil, Interaksi obat)

  • AspirinOAINSModerat

    The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin. (label Ikosapen etil, Peringatan dan perhatian)

  • Aspirin dan dipiridamolantiplateletModerat

    The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin. (label Ikosapen etil, Peringatan dan perhatian)

  • AtorvastatinstatinModerat

    In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (label Ikosapen etil, Peringatan dan perhatian)

  • BivalirudinantikoagulanModerat

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (label Ikosapen etil, Interaksi obat)

  • Butalbital, aspirin, dan kafeinbarbituratModerat

    The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin. (label Ikosapen etil, Peringatan dan perhatian)

  • Butalbital, aspirin, kafein, dan kodeinbarbituratModerat

    The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin. (label Ikosapen etil, Peringatan dan perhatian)

  • DabigatranantikoagulanModerat

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (label Ikosapen etil, Interaksi obat)

  • DipiridamolantiplateletModerat

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (label Ikosapen etil, Interaksi obat)

  • EdoksabanantikoagulanModerat

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (label Ikosapen etil, Interaksi obat)

  • EnoksaparinantikoagulanModerat

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (label Ikosapen etil, Interaksi obat)

  • EptifibatidantiplateletModerat

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (label Ikosapen etil, Interaksi obat)

  • Ezetimib dan simvastatinstatinModerat

    In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (label Ikosapen etil, Peringatan dan perhatian)

  • FluvastatinstatinModerat

    In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (label Ikosapen etil, Peringatan dan perhatian)

  • FondaparinuksantikoagulanModerat

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (label Ikosapen etil, Interaksi obat)

  • HeparinantikoagulanModerat

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (label Ikosapen etil, Interaksi obat)

  • KangrelorantiplateletModerat

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (label Ikosapen etil, Interaksi obat)

  • KlopidogrelantiplateletModerat

    The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin. (label Ikosapen etil, Peringatan dan perhatian)

  • LovastatinstatinModerat

    In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (label Ikosapen etil, Peringatan dan perhatian)

  • Minyak ikan (omega-3)Herbal dan suplemenModerat

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (label Ikosapen etil, Interaksi obat)

  • Orfenadrin, aspirin, dan kafeinpelemas ototModerat

    The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin. (label Ikosapen etil, Peringatan dan perhatian)

  • PitavastatinstatinModerat

    In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (label Ikosapen etil, Peringatan dan perhatian)

  • PrasugrelantiplateletModerat

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (label Ikosapen etil, Interaksi obat)

  • PravastatinstatinModerat

    In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (label Ikosapen etil, Peringatan dan perhatian)

  • RivaroksabanantikoagulanModerat

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (label Ikosapen etil, Interaksi obat)

  • RosuvastatinstatinModerat

    In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (label Ikosapen etil, Peringatan dan perhatian)

  • SilostazolantiplateletModerat

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (label Ikosapen etil, Interaksi obat)

  • SimvastatinstatinModerat

    In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (label Ikosapen etil, Peringatan dan perhatian)

  • TikagrelorantiplateletModerat

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (label Ikosapen etil, Interaksi obat)

  • TirofibanantiplateletModerat

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (label Ikosapen etil, Interaksi obat)

  • WarfarinantikoagulanModerat

    The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin. (label Ikosapen etil, Peringatan dan perhatian)

Periksa Ikosapen etil terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.